{"id":362257,"date":"2025-08-31T07:31:00","date_gmt":"2025-08-31T07:31:00","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-innoviva\/"},"modified":"2025-08-31T07:31:00","modified_gmt":"2025-08-31T07:31:00","slug":"how-to-buy-innoviva","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/","title":{"rendered":"Innoviva, Inc. (INVA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Innoviva, Inc. (INVA) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334027,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-362257","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Innoviva, Inc. (INVA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Innoviva, Inc. (INVA) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Innoviva, Inc. (INVA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Innoviva, Inc. (INVA) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"\u0130la\u00e7 sekt\u00f6r\u00fc f\u0131rsatlar\u0131 i\u00e7in g\u00fcncel fiyat analizi, 2025-2030 tahminleri ve ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ile Innoviva, Inc. (INVA) hisse senedine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"\u0130la\u00e7 sekt\u00f6r\u00fc f\u0131rsatlar\u0131 i\u00e7in g\u00fcncel fiyat analizi, 2025-2030 tahminleri ve ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ile Innoviva, Inc. (INVA) hisse senedine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin."},"intro":"H\u0131zla b\u00fcy\u00fcyen ila\u00e7 sekt\u00f6r\u00fcne yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Innoviva, Inc. (sembol: INVA), b\u00fcy\u00fcme arayan ancak volatilitesi azalt\u0131lm\u0131\u015f yat\u0131r\u0131mc\u0131lar i\u00e7in m\u00fckemmel olan, telif hakk\u0131 gelirlerinin istikrar\u0131 ile ileri d\u00fczey ila\u00e7 geli\u015ftirmeyi benzersiz bir \u015fekilde birle\u015ftiriyor. Bu biyoteknoloji m\u00fccevheri, yerle\u015fik nakit ak\u0131\u015flar\u0131n\u0131 heyecan verici \u00fcr\u00fcn hatt\u0131 potansiyeliyle bir araya getiriyor. INVA'n\u0131n neden dikkatinizi hak etti\u011fini ve yat\u0131r\u0131m yolculu\u011funuzun bir par\u00e7as\u0131 haline nas\u0131l getirebilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"H\u0131zla b\u00fcy\u00fcyen ila\u00e7 sekt\u00f6r\u00fcne yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Innoviva, Inc. (sembol: INVA), b\u00fcy\u00fcme arayan ancak volatilitesi azalt\u0131lm\u0131\u015f yat\u0131r\u0131mc\u0131lar i\u00e7in m\u00fckemmel olan, telif hakk\u0131 gelirlerinin istikrar\u0131 ile ileri d\u00fczey ila\u00e7 geli\u015ftirmeyi benzersiz bir \u015fekilde birle\u015ftiriyor. Bu biyoteknoloji m\u00fccevheri, yerle\u015fik nakit ak\u0131\u015flar\u0131n\u0131 heyecan verici \u00fcr\u00fcn hatt\u0131 potansiyeliyle bir araya getiriyor. INVA'n\u0131n neden dikkatinizi hak etti\u011fini ve yat\u0131r\u0131m yolculu\u011funuzun bir par\u00e7as\u0131 haline nas\u0131l getirebilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 Innoviva Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2> <p>31 A\u011fustos 2025 itibar\u0131yla Innoviva, Inc. (INVA) NASDAQ borsas\u0131nda <strong>18,55 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>5 Kas\u0131m 2025<\/strong> kesinlikle kritik bir tarih\u2014bu tarihte Innoviva \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayacak. Tarihsel olarak, bu a\u00e7\u0131klamalar hisse fiyat\u0131nda \u00f6nemli hareketlere neden olmu\u015ftur.<\/p> <h3>Kazan\u00e7 Etkisi Analizi: Haberler INVA Hissesini Nas\u0131l Hareket Ettiriyor<\/h3> <p>Innoviva'n\u0131n hisseleri kazan\u00e7 a\u00e7\u0131klamalar\u0131na ve d\u00fczenleyici geli\u015fmelere kar\u015f\u0131 ola\u011fan\u00fcst\u00fc duyarl\u0131l\u0131k g\u00f6stermi\u015ftir. \u015eirketin 6 A\u011fustos 2025'te a\u00e7\u0131klad\u0131\u011f\u0131 ikinci \u00e7eyrek sonu\u00e7lar\u0131 bunu m\u00fckemmel \u015fekilde ortaya koydu\u2014analist beklentilerini a\u015farak 0,61 $ EPS ile 0,57 $ tahminlerini geride b\u0131rakt\u0131 ve hemen olumlu bir ivme yaratt\u0131 (<a href=\"https:\/\/www.marketbeat.com\/earnings\/reports\/2025-8-6-innoviva-inc-stock\/\">MarketBeat Kazan\u00e7 Raporu<\/a>).<\/p> <p>Son b\u00fcy\u00fck olaylar\u0131n INVA \u00fczerindeki etkileri \u015f\u00f6yle oldu:<\/p> <table> <thead> <tr> <th>Tarih<\/th> <th>Olay<\/th> <th>Haber \u00d6ncesi Fiyat<\/th> <th>Haber Sonras\u0131 De\u011fi\u015fim<\/th> <\/tr> <\/thead> <tbody> <tr> <td>6 A\u011fu 2025<\/td> <td>2. \u00c7eyrek Kazan\u00e7 A\u015f\u0131m\u0131<\/td> <td>17,80 $<\/td> <td>%4,2 art\u0131\u015f (ertesi g\u00fcn)<\/td> <\/tr> <tr> <td>15 May 2025<\/td> <td>ZEVTERA Lansman \u0130lerlemesi<\/td> <td>16,90 $<\/td> <td>%3,8 art\u0131\u015f (3 g\u00fcn)<\/td> <\/tr> <tr> <td>10 Mar 2025<\/td> <td>Telif Geliri B\u00fcy\u00fcmesi<\/td> <td>16,20 $<\/td> <td>%2,1 art\u0131\u015f (istikrarl\u0131)<\/td> <\/tr> <tr> <td>5 \u015eub 2025<\/td> <td>2024 4. \u00c7eyrek Sonu\u00e7lar\u0131<\/td> <td>15,80 $<\/td> <td>%5,7 art\u0131\u015f (beklentiyi a\u015fma)<\/td> <\/tr> <tr> <td>8 Kas 2024<\/td> <td>Ortakl\u0131k Geni\u015flemesi<\/td> <td>15,20 $<\/td> <td>%4,6 art\u0131\u015f (stratejik)<\/td> <\/tr> <tr> <td>9 A\u011fu 2024<\/td> <td>2024 2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td> <td>14,90 $<\/td> <td>%3,1 d\u00fc\u015f\u00fc\u015f (beklentiyi kar\u015f\u0131layamama)<\/td> <\/tr> <\/tbody> <\/table> <p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Pozitif kazan\u00e7 s\u00fcrprizleri genellikle INVA'y\u0131 birka\u00e7 g\u00fcn i\u00e7inde %4-6 oran\u0131nda y\u00fckseltirken, beklentilerin alt\u0131nda kalan sonu\u00e7lar ge\u00e7ici %2-4 d\u00fc\u015f\u00fc\u015flere neden olur. Hisse, g\u00fc\u00e7l\u00fc temeller sayesinde s\u00fcrekli toparlanmaktad\u0131r.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: Ocak-A\u011fustos 2025<\/h2> <p>Innoviva hisseleri son alt\u0131 ayda etkileyici bir <strong>%17,8 kazan\u00e7<\/strong> sa\u011flad\u0131:<\/p> <p><strong>Ocak<\/strong>: 15,75 $ (tatil sonras\u0131 konsolidasyon)<br\/> <strong>Mart<\/strong>: 16,90 $ (telif geliri g\u00fcc\u00fc)<br\/> <strong>May\u0131s<\/strong>: 17,40 $ (\u00fcr\u00fcn sat\u0131\u015flar\u0131nda h\u0131zlanma)<br\/> <strong>Temmuz<\/strong>: 18,20 $ (kazan\u00e7 beklentisi art\u0131\u015f\u0131)<br\/> <strong>A\u011fustos<\/strong>: 18,55 $ (kazan\u00e7 sonras\u0131 momentum)<\/p> <p>Neden s\u00fcrekli y\u00fckseli\u015f? \u00dc\u00e7 ana etken:<\/p> <ol> <li><strong>Telif Geliri \u0130stikrar\u0131<\/strong>: GSK ortakl\u0131klar\u0131ndan 61,3 milyon $ nakit ak\u0131\u015f\u0131 temeli<\/li> <li><strong>\u00dcr\u00fcn Sat\u0131\u015flar\u0131nda Art\u0131\u015f<\/strong>: Uzmanla\u015fm\u0131\u015f terap\u00f6tiklerde y\u0131ll\u0131k %52 b\u00fcy\u00fcme<\/li> <li><strong>\u00dcr\u00fcn Hatt\u0131 Heyecan\u0131<\/strong>: Zoliflodacin FDA karar\u0131 beklentisi<\/li> <\/ol> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p><strong>2025 (Y\u0131l Sonu)<\/strong>: 22-24 $ aral\u0131\u011f\u0131 (ZEVTERA ticari ba\u015far\u0131s\u0131 + olas\u0131 zoliflodacin onay\u0131) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><\/p> <p><strong>2026 Tahmini<\/strong>: 26-30 $ (yeni \u00fcr\u00fcn lansmanlar\u0131n\u0131n tam y\u0131l katk\u0131s\u0131 + geni\u015fleyen ortakl\u0131klar)<\/p> <p><strong>2028 Tahmini<\/strong>: 35-42 $ (\u00fcr\u00fcn hatt\u0131 olgunla\u015fmas\u0131 + mevcut ila\u00e7lar i\u00e7in yeni endikasyonlar)<\/p> <p><strong>2030 Tahmini<\/strong>: 45-55+ $ (uzmanla\u015fm\u0131\u015f antibiyotiklerde pazar liderli\u011fi + olas\u0131 sat\u0131n alma hedefi)<\/p> <p><strong>Sonu\u00e7<\/strong>: Y\u00f6netilebilir k\u0131sa vadeli volatilite ile ola\u011fan\u00fcst\u00fc uzun vadeli b\u00fcy\u00fcme potansiyeli. Dolar-maliyet ortalamas\u0131 stratejisi i\u00e7in ideal.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>FDA Onay Belirsizli\u011fi<\/strong>: Aral\u0131k 2025'teki zoliflodacin karar\u0131 hisseyi \u00b1%20 etkileyebilir<\/li> <li><strong>Piyasa Volatilitesi<\/strong>: 70,83 RSI k\u0131sa vadeli d\u00fczeltme olas\u0131l\u0131\u011f\u0131 g\u00f6steriyor<\/li> <li><strong>Gelir Konsantrasyonu<\/strong>: GSK telif \u00f6demelerine a\u015f\u0131r\u0131 ba\u011f\u0131ml\u0131l\u0131k (2. \u00e7eyrek gelirinin %61'i)<\/li> <li><strong>D\u00fczenleyici De\u011fi\u015fiklikler<\/strong>: Sa\u011fl\u0131k politikas\u0131 de\u011fi\u015fiklikleri fiyatlama ve geri \u00f6deme \u00fczerinde etkili olabilir<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>Kazan\u00e7 \u0130vmelenmesi<\/strong>: 2. \u00e7eyrek EPS beklentileri %21 a\u015ft\u0131<\/li> <li><strong>\u00dcr\u00fcn Lansmanlar\u0131<\/strong>: ZEVTERA\u00ae ABD lansman\u0131 2025 ortas\u0131nda b\u00fcy\u00fcmeyi tetikliyor<\/li> <li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong>: Antimikrobiyal diren\u00e7 krizi antibiyotik talebini art\u0131r\u0131yor<\/li> <li><strong>G\u00fc\u00e7l\u00fc Bilan\u00e7o<\/strong>: 319,1 milyon $ nakit operasyonel esneklik sa\u011fl\u0131yor<\/li> <li><strong>Analist G\u00fcveni<\/strong>: %100 al\u0131m tavsiyesi ve 40,25 $ ortalama fiyat hedefi<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %5-10'unu biyoteknoloji sekt\u00f6r\u00fcne ay\u0131rarak ba\u015flay\u0131n<\/li> <li><strong>Dolar-Maliyet Ortalamas\u0131<\/strong>: Piyasay\u0131 zamanlamaya \u00e7al\u0131\u015fmak yerine sabit miktarlarda ayl\u0131k yat\u0131r\u0131m yap\u0131n<\/li> <li><strong>5 Kas\u0131m \u0130\u00e7in Uyar\u0131 Kurun<\/strong>: Kazan\u00e7lar, d\u00fc\u015f\u00fc\u015f olursa cazip giri\u015f noktas\u0131 sa\u011flayabilir<\/li> <li><strong>FDA Takvimini Takip Edin<\/strong>: 15 Aral\u0131k'taki zoliflodacin karar\u0131 b\u00fcy\u00fck kataliz\u00f6r<\/li> <\/ol> <p>Espiri: \"INVA ticareti antibiyotik tedavisi gibidir\u2014do\u011fru dozda ve zamanda olmal\u0131. Heyecana fazla kap\u0131l\u0131rsan\u0131z yan etkiler olabilir; az al\u0131rsan\u0131z enfeksiyonla sava\u015fan k\u00e2rlar\u0131 ka\u00e7\u0131r\u0131rs\u0131n\u0131z!\"<\/p> <h2>\u2705 Innoviva, Inc. (INVA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr> <th>Ad\u0131m<\/th> <th>\u0130\u015flem<\/th> <th>Neden \u00d6nemli<\/th> <\/tr> <\/thead> <tbody> <tr> <td>1<\/td> <td>Ticaret Platformu Se\u00e7in<\/td> <td>NASDAQ eri\u015fimi ve d\u00fc\u015f\u00fck komisyon yap\u0131s\u0131 sa\u011flay\u0131n<\/td> <\/tr> <tr> <td>2<\/td> <td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td> <td>Y\u00f6netilebilir bir miktarla ba\u015flay\u0131n\u2014100 $ bile yeterli<\/td> <\/tr> <tr> <td>3<\/td> <td>\"INVA\" Aramas\u0131 Yap\u0131n<\/td> <td>Kesinlik i\u00e7in do\u011fru sembol\u00fc kullan\u0131n<\/td> <\/tr> <tr> <td>4<\/td> <td>Sipari\u015f T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td> <td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emri \u00f6nerilir<\/td> <\/tr> <tr> <td>5<\/td> <td>\u0130nceleyin ve Onaylay\u0131n<\/td> <td>Sipari\u015f detaylar\u0131n\u0131 iki kez kontrol edin<\/td> <\/tr> <tr> <td>6<\/td> <td>Fiyat Uyar\u0131lar\u0131 Kurun<\/td> <td>Gelecekteki kararlar i\u00e7in \u00f6nemli seviyeleri takip edin<\/td> <\/tr> <tr> <td>7<\/td> <td>Yat\u0131r\u0131m Tezinizi Belgeleyin<\/td> <td>Yat\u0131r\u0131m nedenlerinizi gelecekte referans i\u00e7in not al\u0131n<\/td> <\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2> <p>Pocket Option, yeni ba\u015flayanlar i\u00e7in hisse senedi eri\u015fimini devrim niteli\u011finde kolayla\u015ft\u0131r\u0131r:<\/p> <ul> <li><strong>Minimum depozito sadece 5 $<\/strong>\u2014stratejileri d\u00fc\u015f\u00fck riskle test edin<\/li> <li><strong>1 dakikal\u0131k do\u011frulama<\/strong>\u2014tek belge ile an\u0131nda i\u015flem yap\u0131n<\/li> <li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong>\u2014kripto para ve banka transferleri dahil<\/li> <li><strong>Par\u00e7al\u0131 hisse al\u0131m\u0131<\/strong>\u2014pahal\u0131 hisselerin b\u00f6l\u00fcmlerini sat\u0131n al\u0131n<\/li> <li><strong>Ger\u00e7ek zamanl\u0131 piyasa verisi<\/strong>\u2014gecikme olmadan bilin\u00e7li kararlar al\u0131n<\/li> <\/ul> <h2>\ud83c\udf0d Innoviva 2025'te: \u0130la\u00e7ta Yenilik Lideri<\/h2> <p>Innoviva, uzmanla\u015fm\u0131\u015f ila\u00e7lar alan\u0131nda benzersiz \u00e7ift modelle hakimiyet kuruyor: yerle\u015fik solunum ila\u00e7lar\u0131ndan istikrarl\u0131 telif geliri ve yenilik\u00e7i anti-enfektiflerden y\u00fcksek b\u00fcy\u00fcme potansiyeli. \u015eirketin antimikrobiyal diren\u00e7le m\u00fccadeleye stratejik odaklanmas\u0131\u2014her y\u0131l milyonlarca insan\u0131 etkileyen k\u00fcresel bir sa\u011fl\u0131k krizi\u2014uzun vadeli ba\u015far\u0131 i\u00e7in m\u00fckemmel bir konum sa\u011fl\u0131yor.<\/p> <p>Mevcut piyasa konumu: <strong>1,3 milyar $ piyasa de\u011feri<\/strong> ve %85,94 br\u00fct marj ile ola\u011fan\u00fcst\u00fc operasyonel verimlilik (<a href=\"https:\/\/simplywall.st\/stocks\/us\/pharmaceuticals-biotech\/nasdaq-inva\/innoviva\">Simply Wall St<\/a>).<\/p> <p><strong>\u0130lgin\u00e7 Bilgi<\/strong>: Innoviva'n\u0131n yat\u0131r\u0131m kolu, ila\u00e7 direncine kar\u015f\u0131 hedeflenen faj terapilerini ilerletmek i\u00e7in Armata Pharmaceuticals'a 10 milyon $ kredi sa\u011flad\u0131\u2014t\u0131bb\u0131n en b\u00fcy\u00fck zorluklar\u0131ndan birini \u00e7\u00f6zme taahh\u00fcd\u00fcn\u00fc g\u00f6sterirken gelecekteki gelir ak\u0131\u015flar\u0131 yaratma potansiyeli ta\u015f\u0131yor.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Innoviva Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2>\n<p>31 A\u011fustos 2025 itibar\u0131yla Innoviva, Inc. (INVA) NASDAQ borsas\u0131nda <strong>18,55 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>5 Kas\u0131m 2025<\/strong> kesinlikle kritik bir tarih\u2014bu tarihte Innoviva \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayacak. Tarihsel olarak, bu a\u00e7\u0131klamalar hisse fiyat\u0131nda \u00f6nemli hareketlere neden olmu\u015ftur.<\/p>\n<h3>Kazan\u00e7 Etkisi Analizi: Haberler INVA Hissesini Nas\u0131l Hareket Ettiriyor<\/h3>\n<p>Innoviva&#8217;n\u0131n hisseleri kazan\u00e7 a\u00e7\u0131klamalar\u0131na ve d\u00fczenleyici geli\u015fmelere kar\u015f\u0131 ola\u011fan\u00fcst\u00fc duyarl\u0131l\u0131k g\u00f6stermi\u015ftir. \u015eirketin 6 A\u011fustos 2025&#8217;te a\u00e7\u0131klad\u0131\u011f\u0131 ikinci \u00e7eyrek sonu\u00e7lar\u0131 bunu m\u00fckemmel \u015fekilde ortaya koydu\u2014analist beklentilerini a\u015farak 0,61 $ EPS ile 0,57 $ tahminlerini geride b\u0131rakt\u0131 ve hemen olumlu bir ivme yaratt\u0131 (<a href=\"https:\/\/www.marketbeat.com\/earnings\/reports\/2025-8-6-innoviva-inc-stock\/\">MarketBeat Kazan\u00e7 Raporu<\/a>).<\/p>\n<p>Son b\u00fcy\u00fck olaylar\u0131n INVA \u00fczerindeki etkileri \u015f\u00f6yle oldu:<\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>6 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7 A\u015f\u0131m\u0131<\/td>\n<td>17,80 $<\/td>\n<td>%4,2 art\u0131\u015f (ertesi g\u00fcn)<\/td>\n<\/tr>\n<tr>\n<td>15 May 2025<\/td>\n<td>ZEVTERA Lansman \u0130lerlemesi<\/td>\n<td>16,90 $<\/td>\n<td>%3,8 art\u0131\u015f (3 g\u00fcn)<\/td>\n<\/tr>\n<tr>\n<td>10 Mar 2025<\/td>\n<td>Telif Geliri B\u00fcy\u00fcmesi<\/td>\n<td>16,20 $<\/td>\n<td>%2,1 art\u0131\u015f (istikrarl\u0131)<\/td>\n<\/tr>\n<tr>\n<td>5 \u015eub 2025<\/td>\n<td>2024 4. \u00c7eyrek Sonu\u00e7lar\u0131<\/td>\n<td>15,80 $<\/td>\n<td>%5,7 art\u0131\u015f (beklentiyi a\u015fma)<\/td>\n<\/tr>\n<tr>\n<td>8 Kas 2024<\/td>\n<td>Ortakl\u0131k Geni\u015flemesi<\/td>\n<td>15,20 $<\/td>\n<td>%4,6 art\u0131\u015f (stratejik)<\/td>\n<\/tr>\n<tr>\n<td>9 A\u011fu 2024<\/td>\n<td>2024 2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>14,90 $<\/td>\n<td>%3,1 d\u00fc\u015f\u00fc\u015f (beklentiyi kar\u015f\u0131layamama)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Pozitif kazan\u00e7 s\u00fcrprizleri genellikle INVA&#8217;y\u0131 birka\u00e7 g\u00fcn i\u00e7inde %4-6 oran\u0131nda y\u00fckseltirken, beklentilerin alt\u0131nda kalan sonu\u00e7lar ge\u00e7ici %2-4 d\u00fc\u015f\u00fc\u015flere neden olur. Hisse, g\u00fc\u00e7l\u00fc temeller sayesinde s\u00fcrekli toparlanmaktad\u0131r.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: Ocak-A\u011fustos 2025<\/h2>\n<p>Innoviva hisseleri son alt\u0131 ayda etkileyici bir <strong>%17,8 kazan\u00e7<\/strong> sa\u011flad\u0131:<\/p>\n<p><strong>Ocak<\/strong>: 15,75 $ (tatil sonras\u0131 konsolidasyon)<br \/> <strong>Mart<\/strong>: 16,90 $ (telif geliri g\u00fcc\u00fc)<br \/> <strong>May\u0131s<\/strong>: 17,40 $ (\u00fcr\u00fcn sat\u0131\u015flar\u0131nda h\u0131zlanma)<br \/> <strong>Temmuz<\/strong>: 18,20 $ (kazan\u00e7 beklentisi art\u0131\u015f\u0131)<br \/> <strong>A\u011fustos<\/strong>: 18,55 $ (kazan\u00e7 sonras\u0131 momentum)<\/p>\n<p>Neden s\u00fcrekli y\u00fckseli\u015f? \u00dc\u00e7 ana etken:<\/p>\n<ol>\n<li><strong>Telif Geliri \u0130stikrar\u0131<\/strong>: GSK ortakl\u0131klar\u0131ndan 61,3 milyon $ nakit ak\u0131\u015f\u0131 temeli<\/li>\n<li><strong>\u00dcr\u00fcn Sat\u0131\u015flar\u0131nda Art\u0131\u015f<\/strong>: Uzmanla\u015fm\u0131\u015f terap\u00f6tiklerde y\u0131ll\u0131k %52 b\u00fcy\u00fcme<\/li>\n<li><strong>\u00dcr\u00fcn Hatt\u0131 Heyecan\u0131<\/strong>: Zoliflodacin FDA karar\u0131 beklentisi<\/li>\n<\/ol>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p><strong>2025 (Y\u0131l Sonu)<\/strong>: 22-24 $ aral\u0131\u011f\u0131 (ZEVTERA ticari ba\u015far\u0131s\u0131 + olas\u0131 zoliflodacin onay\u0131) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><\/p>\n<p><strong>2026 Tahmini<\/strong>: 26-30 $ (yeni \u00fcr\u00fcn lansmanlar\u0131n\u0131n tam y\u0131l katk\u0131s\u0131 + geni\u015fleyen ortakl\u0131klar)<\/p>\n<p><strong>2028 Tahmini<\/strong>: 35-42 $ (\u00fcr\u00fcn hatt\u0131 olgunla\u015fmas\u0131 + mevcut ila\u00e7lar i\u00e7in yeni endikasyonlar)<\/p>\n<p><strong>2030 Tahmini<\/strong>: 45-55+ $ (uzmanla\u015fm\u0131\u015f antibiyotiklerde pazar liderli\u011fi + olas\u0131 sat\u0131n alma hedefi)<\/p>\n<p><strong>Sonu\u00e7<\/strong>: Y\u00f6netilebilir k\u0131sa vadeli volatilite ile ola\u011fan\u00fcst\u00fc uzun vadeli b\u00fcy\u00fcme potansiyeli. Dolar-maliyet ortalamas\u0131 stratejisi i\u00e7in ideal.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>FDA Onay Belirsizli\u011fi<\/strong>: Aral\u0131k 2025&#8217;teki zoliflodacin karar\u0131 hisseyi \u00b1%20 etkileyebilir<\/li>\n<li><strong>Piyasa Volatilitesi<\/strong>: 70,83 RSI k\u0131sa vadeli d\u00fczeltme olas\u0131l\u0131\u011f\u0131 g\u00f6steriyor<\/li>\n<li><strong>Gelir Konsantrasyonu<\/strong>: GSK telif \u00f6demelerine a\u015f\u0131r\u0131 ba\u011f\u0131ml\u0131l\u0131k (2. \u00e7eyrek gelirinin %61&#8217;i)<\/li>\n<li><strong>D\u00fczenleyici De\u011fi\u015fiklikler<\/strong>: Sa\u011fl\u0131k politikas\u0131 de\u011fi\u015fiklikleri fiyatlama ve geri \u00f6deme \u00fczerinde etkili olabilir<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>Kazan\u00e7 \u0130vmelenmesi<\/strong>: 2. \u00e7eyrek EPS beklentileri %21 a\u015ft\u0131<\/li>\n<li><strong>\u00dcr\u00fcn Lansmanlar\u0131<\/strong>: ZEVTERA\u00ae ABD lansman\u0131 2025 ortas\u0131nda b\u00fcy\u00fcmeyi tetikliyor<\/li>\n<li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong>: Antimikrobiyal diren\u00e7 krizi antibiyotik talebini art\u0131r\u0131yor<\/li>\n<li><strong>G\u00fc\u00e7l\u00fc Bilan\u00e7o<\/strong>: 319,1 milyon $ nakit operasyonel esneklik sa\u011fl\u0131yor<\/li>\n<li><strong>Analist G\u00fcveni<\/strong>: %100 al\u0131m tavsiyesi ve 40,25 $ ortalama fiyat hedefi<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %5-10&#8217;unu biyoteknoloji sekt\u00f6r\u00fcne ay\u0131rarak ba\u015flay\u0131n<\/li>\n<li><strong>Dolar-Maliyet Ortalamas\u0131<\/strong>: Piyasay\u0131 zamanlamaya \u00e7al\u0131\u015fmak yerine sabit miktarlarda ayl\u0131k yat\u0131r\u0131m yap\u0131n<\/li>\n<li><strong>5 Kas\u0131m \u0130\u00e7in Uyar\u0131 Kurun<\/strong>: Kazan\u00e7lar, d\u00fc\u015f\u00fc\u015f olursa cazip giri\u015f noktas\u0131 sa\u011flayabilir<\/li>\n<li><strong>FDA Takvimini Takip Edin<\/strong>: 15 Aral\u0131k&#8217;taki zoliflodacin karar\u0131 b\u00fcy\u00fck kataliz\u00f6r<\/li>\n<\/ol>\n<p>Espiri: &#8220;INVA ticareti antibiyotik tedavisi gibidir\u2014do\u011fru dozda ve zamanda olmal\u0131. Heyecana fazla kap\u0131l\u0131rsan\u0131z yan etkiler olabilir; az al\u0131rsan\u0131z enfeksiyonla sava\u015fan k\u00e2rlar\u0131 ka\u00e7\u0131r\u0131rs\u0131n\u0131z!&#8221;<\/p>\n<h2>\u2705 Innoviva, Inc. (INVA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve d\u00fc\u015f\u00fck komisyon yap\u0131s\u0131 sa\u011flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Y\u00f6netilebilir bir miktarla ba\u015flay\u0131n\u2014100 $ bile yeterli<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;INVA&#8221; Aramas\u0131 Yap\u0131n<\/td>\n<td>Kesinlik i\u00e7in do\u011fru sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Sipari\u015f T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emri \u00f6nerilir<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>Sipari\u015f detaylar\u0131n\u0131 iki kez kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Fiyat Uyar\u0131lar\u0131 Kurun<\/td>\n<td>Gelecekteki kararlar i\u00e7in \u00f6nemli seviyeleri takip edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Yat\u0131r\u0131m Tezinizi Belgeleyin<\/td>\n<td>Yat\u0131r\u0131m nedenlerinizi gelecekte referans i\u00e7in not al\u0131n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2>\n<p>Pocket Option, yeni ba\u015flayanlar i\u00e7in hisse senedi eri\u015fimini devrim niteli\u011finde kolayla\u015ft\u0131r\u0131r:<\/p>\n<ul>\n<li><strong>Minimum depozito sadece 5 $<\/strong>\u2014stratejileri d\u00fc\u015f\u00fck riskle test edin<\/li>\n<li><strong>1 dakikal\u0131k do\u011frulama<\/strong>\u2014tek belge ile an\u0131nda i\u015flem yap\u0131n<\/li>\n<li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong>\u2014kripto para ve banka transferleri dahil<\/li>\n<li><strong>Par\u00e7al\u0131 hisse al\u0131m\u0131<\/strong>\u2014pahal\u0131 hisselerin b\u00f6l\u00fcmlerini sat\u0131n al\u0131n<\/li>\n<li><strong>Ger\u00e7ek zamanl\u0131 piyasa verisi<\/strong>\u2014gecikme olmadan bilin\u00e7li kararlar al\u0131n<\/li>\n<\/ul>\n<h2>\ud83c\udf0d Innoviva 2025&#8217;te: \u0130la\u00e7ta Yenilik Lideri<\/h2>\n<p>Innoviva, uzmanla\u015fm\u0131\u015f ila\u00e7lar alan\u0131nda benzersiz \u00e7ift modelle hakimiyet kuruyor: yerle\u015fik solunum ila\u00e7lar\u0131ndan istikrarl\u0131 telif geliri ve yenilik\u00e7i anti-enfektiflerden y\u00fcksek b\u00fcy\u00fcme potansiyeli. \u015eirketin antimikrobiyal diren\u00e7le m\u00fccadeleye stratejik odaklanmas\u0131\u2014her y\u0131l milyonlarca insan\u0131 etkileyen k\u00fcresel bir sa\u011fl\u0131k krizi\u2014uzun vadeli ba\u015far\u0131 i\u00e7in m\u00fckemmel bir konum sa\u011fl\u0131yor.<\/p>\n<p>Mevcut piyasa konumu: <strong>1,3 milyar $ piyasa de\u011feri<\/strong> ve %85,94 br\u00fct marj ile ola\u011fan\u00fcst\u00fc operasyonel verimlilik (<a href=\"https:\/\/simplywall.st\/stocks\/us\/pharmaceuticals-biotech\/nasdaq-inva\/innoviva\">Simply Wall St<\/a>).<\/p>\n<p><strong>\u0130lgin\u00e7 Bilgi<\/strong>: Innoviva&#8217;n\u0131n yat\u0131r\u0131m kolu, ila\u00e7 direncine kar\u015f\u0131 hedeflenen faj terapilerini ilerletmek i\u00e7in Armata Pharmaceuticals&#8217;a 10 milyon $ kredi sa\u011flad\u0131\u2014t\u0131bb\u0131n en b\u00fcy\u00fck zorluklar\u0131ndan birini \u00e7\u00f6zme taahh\u00fcd\u00fcn\u00fc g\u00f6sterirken gelecekteki gelir ak\u0131\u015flar\u0131 yaratma potansiyeli ta\u015f\u0131yor.<\/p>\n"},"faq":[{"question":"Innoviva hisseleri nereden al\u0131nabilir?","answer":"Innoviva hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"INVA hissesinin gelecekteki fiyat tahmini nedir?","answer":"2025 sonunda 22-24 $ aral\u0131\u011f\u0131nda, 2030 y\u0131l\u0131nda ise 45-55 $ ve \u00fczeri seviyelerde olmas\u0131 beklenmektedir."},{"question":"Innoviva'n\u0131n ana gelir kaynaklar\u0131 nelerdir?","answer":"\u015eirketin ana gelir kaynaklar\u0131 GSK ortakl\u0131klar\u0131ndan elde edilen telif haklar\u0131 ve uzmanla\u015fm\u0131\u015f terap\u00f6tik \u00fcr\u00fcn sat\u0131\u015flar\u0131d\u0131r."},{"question":"FDA onay s\u00fcreci Innoviva hisselerini nas\u0131l etkiler?","answer":"\u00d6zellikle zoliflodacin i\u00e7in Aral\u0131k 2025'te beklenen FDA karar\u0131, hisse fiyat\u0131nda %20'ye varan dalgalanmalara neden olabilir."},{"question":"Yeni ba\u015flayanlar Innoviva hissesi al\u0131rken nelere dikkat etmeli?","answer":"K\u00fc\u00e7\u00fck yat\u0131r\u0131mlarla ba\u015flay\u0131p, dolar-maliyet ortalamas\u0131 yaparak, \u00f6nemli tarihleri takip ederek ve piyasa haberlerini izleyerek riskleri azaltabilirler."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Innoviva hisseleri nereden al\u0131nabilir?","answer":"Innoviva hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"INVA hissesinin gelecekteki fiyat tahmini nedir?","answer":"2025 sonunda 22-24 $ aral\u0131\u011f\u0131nda, 2030 y\u0131l\u0131nda ise 45-55 $ ve \u00fczeri seviyelerde olmas\u0131 beklenmektedir."},{"question":"Innoviva'n\u0131n ana gelir kaynaklar\u0131 nelerdir?","answer":"\u015eirketin ana gelir kaynaklar\u0131 GSK ortakl\u0131klar\u0131ndan elde edilen telif haklar\u0131 ve uzmanla\u015fm\u0131\u015f terap\u00f6tik \u00fcr\u00fcn sat\u0131\u015flar\u0131d\u0131r."},{"question":"FDA onay s\u00fcreci Innoviva hisselerini nas\u0131l etkiler?","answer":"\u00d6zellikle zoliflodacin i\u00e7in Aral\u0131k 2025'te beklenen FDA karar\u0131, hisse fiyat\u0131nda %20'ye varan dalgalanmalara neden olabilir."},{"question":"Yeni ba\u015flayanlar Innoviva hissesi al\u0131rken nelere dikkat etmeli?","answer":"K\u00fc\u00e7\u00fck yat\u0131r\u0131mlarla ba\u015flay\u0131p, dolar-maliyet ortalamas\u0131 yaparak, \u00f6nemli tarihleri takip ederek ve piyasa haberlerini izleyerek riskleri azaltabilirler."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Innoviva, Inc. (INVA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Innoviva, Inc. (INVA) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innoviva, Inc. (INVA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Innoviva, Inc. (INVA) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-31T07:31:00+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Innoviva, Inc. (INVA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Innoviva, Inc. (INVA) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-31T07:31:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/\",\"name\":\"Innoviva, Inc. (INVA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Innoviva, Inc. (INVA) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"datePublished\":\"2025-08-31T07:31:00+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innoviva, Inc. (INVA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Innoviva, Inc. (INVA) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innoviva, Inc. (INVA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Innoviva, Inc. (INVA) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/","og_locale":"tr_TR","og_type":"article","og_title":"Innoviva, Inc. (INVA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Innoviva, Inc. (INVA) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-31T07:31:00+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Innoviva, Inc. (INVA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Innoviva, Inc. (INVA) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-31T07:31:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/","name":"Innoviva, Inc. (INVA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Innoviva, Inc. (INVA) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","datePublished":"2025-08-31T07:31:00+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-innoviva\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Innoviva, Inc. (INVA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Innoviva, Inc. (INVA) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":362256,"slug":"how-to-buy-innoviva","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Innoviva, Inc. (INVA) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Innoviva, Inc. (INVA)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-innoviva\/"},"pt_AA":{"locale":"pt_AA","id":362260,"slug":"how-to-buy-innoviva","post_title":"Como comprar a\u00e7\u00f5es da Innoviva, Inc. (INVA) - Investimento em a\u00e7\u00f5es da Innoviva, Inc. (INVA)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-innoviva\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/362257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=362257"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/362257\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334027"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=362257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=362257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=362257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}